

The Proposal and Statement by the Nomination Committee

The Nomination Committee has consisted of: Hans Wigzell (Chairman), appointed by Insamlingsstiftelsen för främjande och utveckling av medicinsk forskning vid KI; Jack Li, appointed by invoX Pharma Ltd; Anders Hallberg; Jan Dworsky, appointed by Swedbank Robur Microcap fond; Peter Markborn, appointed by Styviken Invest AS.

The Nomination Committee's work

Within the context of its work for the Annual General Meeting 2026, the Nomination Committee (the "**Committee**") interviewed the current directors and took part of other relevant information to fully understand the company situation, the primary challenges and opportunities. The Committee also reviewed the Board of Directors' internal evaluation of its work. The Committee held four minuted meetings.

The Nomination Committee's reasoned statement

What is mentioned in the first section above has formed the basis for the Committee's considerations about the composition of the Board of Directors and main requirements that should be imposed on the members of the Board of Directors. The Committee also paid attention to independence issues, other assignments that the directors have in other companies and gender balance.

When determining the proposed members of the Board of Directors suitability as members of the Board of Directors in KDventures, other engagements by the proposed directors as well as potential conflicts of interest have been considered and it is deemed that such issues, if arisen can be addressed and managed through the normal procedures in the Board of Directors' work. The Committee believes that the proposed Board of Directors, with respect to the company's operations, stage of development and other circumstances, will have an appropriate composition characterized by diversity and breadth in terms of the expertise, experience and background. The Committee also believes that it is possible for all proposed directors to make available sufficient time for the performance of the assignment.

The formal independent requirements according to the Swedish Code of Corporate Governance are met. The proposal by the Committee does also meet the requirements in the Swedish Code of Corporate Governance and the Swedish Corporate Governance board's ambition to achieve gender balance on the board of listed companies.

The Nomination Committee's proposal

The Nomination Committee proposes that the Annual General Meeting resolves as follows:

- Lawyer Annika Andersson (Cirio Law Firm) is appointed to chair the Annual General Meeting.
- The number of directors will be five and no deputies will be appointed.
- The number of auditors will be one and no deputy auditor will be appointed.
- The chairman will be paid a fixed amount of SEK 400,000 to be paid out in proportion to board meetings attended. All other directors will be paid a fixed amount of SEK 200,000 to be paid out in proportion to board meetings attended. The fees to the directors remain unchanged compared to previous year.
- The auditors will be paid as per invoice.
- Re-election of the directors Ben Toogood and Anna Lefevre Skjöldebrand.
- Election of Anders Hallberg, Anders Bladh and Angelica Loskog as directors.

Anders Hallberg was Born 1973. He holds a Master's degree in Economics and Bachelor's degree in Business Administration from Lund University. His other appointments are Chairman of the Board of Medivir AB and Board member of Hallberg Management AB. His previous assignments include founder of HealthInvest Partners AB, Analyst and portfolio manager in the healthcare sector at Carnegie Investment Bank AB / Carnegie Asset Management AB. He is independent in relation to the Company and its executive management. He is not independent in relation to the Company's major shareholders. Anders holds 92,800,000 shares in the Company.

Anders Bladh was Born 1958. He holds a Master's degree in International Business Administration from the University of Uppsala. His other appointments are Chairman of the Board of Intervalor AB, Rimturs AB and Ribbskottet AB and Board member of Xspray Pharma AB and Umecrine Cognition AB. His previous assignments include Senior Vice President of Handelsbanken International and Corporate Finance departments, CEO of two real estate companies based in Holland and Board member of Erik Penser Funds, Medirox AB and Distit AB. Founder and CEO of Intervalor AB. He is independent in relation to the Company, its executive management and to the Company's major shareholders. Anders holds 1,000,000 shares in the Company.

Angelica Loskog was Born 1973. She holds a PhD in Clinical Immunology from Uppsala University. Her other appointments are CEO and Board member of Lokon Pharma AB and acts as a scientific advisor to the investment company Nexttobe AB, Chairman of the Board of Repos Pharma AB and Board member of Medivir AB. Her previous assignments include Chairman of the Board of Vivolux AB and Board member of Chemilia AB, Bioimics AB and Hansa Biopharma AB. She is independent in relation to the Company, its executive management and to the Company's major shareholders. Angelica has no holdings in the Company.

- Election of Anders Hallberg as Chairman of the Board of Directors.
- The Nomination Committee proposes that voting shall take place individually.
- Re-election of Ernst & Young Aktiebolag as auditor in accordance with the audit committee's recommendation, currently with Oskar Wall as auditor in charge, for the time until the end of the 2027 Annual General Meeting.

The Nomination Committee, Solna in April 2026